1. A Phase IIb, randomized, placebo‐controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Issue 8 (4th March 2013) Authors: Ferrannini, E.; Seman, L.; Seewaldt‐Becker, E.; Hantel, S.; Pinnetti, S.; Woerle, H. J. Journal: Diabetes, obesity & metabolism Issue: Volume 15:Issue 8(2013:Aug.) Page Start: 721 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. Issue 7 (17th February 2013) Authors: Heise, T.; Seewaldt‐Becker, E.; Macha, S.; Hantel, S.; Pinnetti, S.; Seman, L.; Woerle, H. J. Journal: Diabetes, obesity & metabolism Issue: Volume 15:Issue 7(2013:Jul.) Page Start: 613 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗